Pharma: Other News To Note
Ranbaxy Laboratories Inc., of Princeton, N.J., a wholly owned subsidiary of Ranbaxy Laboratories Ltd., is planning to launch Absorica (isotretinoin) in the fourth quarter, now that the FDA has approved the drug for the treatment of severe recalcitrant nodular acne. Absorica is partnered with Mississauga, Ontario-based Cipher Pharmaceuticals Inc., which will receive royalties on net sales.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.